Ways to improve the results of conservative therapy of malignant tumors of the head and neck organs. Part I. The current state of the issue (review)

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The review analyzes the results of conservative therapy of patients with the head and neck cancer. Despite the use of modern radiation and drug technologies, the results of treatment of locally advanced forms of head and neck cancers and relapses are not satisfactory. The most effective is the simultaneous use of modified radiation and chemotherapy regimens. However, the implementation of the treatment plan with this method is limited to the development of pronounced early and late toxic effects on normal tissues and organs. The radiosensitizing effect of targeted therapy was also analyzed.

作者简介

Orazakhmet Kurpeshev

Siberian Research Institute of Hyperthermia

编辑信件的主要联系方式.
Email: kurpeshev-ok@yandex.ru
ORCID iD: 0000-0003-3219-1596
SPIN 代码: 2467-6046

MD, Dr. Sci. (Medicine)

俄罗斯联邦, 56–47 Volodarsky street, 197706 St. Petersburg

参考

  1. SEER Cancer Statistics Review (CSR) 1975–2015 [internet] [updated 10 Sep 2018]. Available from: https://seer.cancer.gov/archive/csr/1975_2015/
  2. The state of cancer care for the population of Russia in 2022. Kaprin AD, Starinsky VV, Shakhzadova AO, editors; Moscow: MNIOI named PA. Herzen — branch of NMRRC; 2023. 239 p. (In Russ).
  3. Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v184–186. doi: 10.1093/annonc/mdq185
  4. Lefebvre JL, Lartigau E, Kara A, Sarini J. Oral Cavity, Pharynx and Larynx Cancer. In: Prognostic Factors in Cancer. Head and Neck Tumors; New York: A. John Wiley and Sons, Inc. 2001. P. 151–166. doi: 10.1002/0471463736.tnmp11
  5. Laramore GE, Coltrera MD, Karen JH. Tumors of Head and Neck. In: Cliniсal Oncology. 8th edition. Rubin Ph, editor. Philadelphia: W.B. Saunders Co., 2001. P. 405–461.
  6. Parkhomenko LB, Krutilina NI. Results of chemoradiotherapy with altered fractionation for locally advanced larynx cancer. Oncology Journal. 2021;15(1(57)):50–56. EDN: VXFUTM
  7. Schiff BA. Overview of Head and Neck Tumors. MSD Handbook. Professional version. Reviewed/Revised Dec 2022. Available from: https://www.msdmanuals.com/ru
  8. Oral Cavity Cancer. Clinical Practice Guideline HN-002 – Version 2. Clinical Effective December, 2023]. Available from: www.ahs.ca/guru
  9. Laskar SG, Agarwal JP, Srinivas C, Dinshaw KA. Radiotherapeutic management of locally advanced head and neck cancer. Expert Rev Anticancer Ther. 2006;6:405–417. doi: 10.1586/14737140.6.3.405
  10. Fan KH, Chen YC, Lin CY, et al. Postoperative radiotherapy with or without concurrent chemotherapy for oral squamous cell carcinoma in patients with three or more minor risk factors: a propensity score matching analysis. Radiat Oncol. 2017;12(1):184. doi: 10.1186/s13014-017-0910-0
  11. Huang SH, O´Sullivan B. Oral cancer: Current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal. 2013;18(2):e233–240. doi: 10.4317/medoral.18772
  12. Gevorkov AR, Boiko AV, Zavalishina LE, et al. Separate conservative and combined treatment for tongue cancer. P.A. Herzen Journal of Oncology. 2014;4:25–29. EDN: TAIZSJ
  13. Donald PJ. The difficult case in head and neck cancer surgery. New York: Thieme Medical Publishers; 2009. Р. 541. doi: 10.1055/b-002-59197
  14. Leemans R. Strategies for non-resectable tumors; 3rd trends in head and neck oncology. Rome; 2011.
  15. Hassanein KA, Musgrove BT, Bradbury E. Psychological outcome of patients following treatment of oral cancer and its relation with functional status and coping mechanisms. J Craniomaxillofac Surg. 2005;33(6):404–409. doi: 10.1016/j.jcms.2005.05.005
  16. Hasegawa T, Yatagai N, Furukawa T, et al. The prospective evaluation and risk factors of dysphagia after surgery in patients with oral cancer. J Otolaryngol Head & Neck Surg. 2021;4. doi: 10.1186/s40463-020-00479-6
  17. Nagy J, Braunitzer G, Antal M, et al. Quality of life in head and neck cancer patients after tumor therapy and subsequent rehabilitation: an exploratory study. Qual Life Res. 2014;23(1):135–143. doi: 10.1007/s11136-013-0446-1
  18. Kropotov MA. Organ-preserving and reconstructive operations on the lower jaw in the combined treatment of cancer of the oral mucosa [dissertation]. Moscow; 2004. (In Russ). EDN: NPXTZJ
  19. Kropotov MA, Epikhina AV, Udintsov DK, Il’kaev КD. Oropharyngeal cancer: the aspects of surgical treatment. Bulletin of Otorhinolaryngology. 2013;6:13–17. EDN: NYACZZ
  20. Rebrikova IV, Polyakov AP. Salvage surgery in the treatment of patients with recurrent squamous cell carcinoma of the oral cavity. P.A. Herzen Journal of Oncology. 2022;11(1):60–63. doi: 10.17116/onkolog20221101160
  21. Li Y, Jiang Y, Qiu B, et al. Current radiotherapy for recurrent head and neck cancer in the modern era: a state of the art review. J Trans Med. 2022;20:566. doi: 10.1186/s12967-022-03774-0
  22. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30:281–288. doi: 10.1002/hed.20697
  23. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007;25:4800–4805. doi: 10.1200/JCO.2006.07.9194
  24. Kaprin AD, Boiko AV, Gevorkov AR, Bolotina LV. The current state of radiotherapy in patients with oropharyngeal squamous cell carcinoma. A radiation therapist’s view. P.A. Herzen Journal of Oncology. 2017;6(4):4–8. doi: 10.17116/onkolog2017644-8
  25. Boyko AV, Gevorkov AR, Semin DYu. Oropharyngeal cancer. In: National guidelines: Therapeutic radiology. Kaprin AD, Mardinsky YuS, editors. Moscow: GEOTAR-Media; 2018. P. 218–271.
  26. Carvalho AL; Magrin J, Kowalski LP. Sites of recurrence in oral and oropharyngeal cancers according to the treatment approach. Oral Diseases. 2003;9(3):112–118. doi: 10.1034/j.1601-0825.2003.01750.x
  27. Horiot JC, Fur RL, N’Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngecal carcinoma final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother. Oncol. 1992;25(4):231–241. doi: 10.1016/0167-8140(92)90242-m
  28. Skladowski K, Maciejewski B, Golen M, et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys. 2006;66(3):706-13. doi: 10.1016/j.ijrobp.2006.05.026
  29. Zhu B, Kou C, Bai W, et al. Accelerated Hyperfractionated Radiotherapy versus Conventional Fractionation Radiotherapy for Head and Neck Cancer: A Meta-Analysis of Randomized Controlled Trials. J Oncol. 2019;2019:7634746. doi: 10.1155/2019/7634746
  30. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362(9388):933–940. doi: 10.1016/s0140-6736(03)14361-9
  31. Overgaard J, Mohanti BK, Begum N, et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomized, multicentre trial. Lancet Oncol. 2010;11(6):553–560. doi: 10.1016/S1470-2045(10)70072-3
  32. Bourhis J, Overgaard J, Audry H, Ang KK, et al; Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368(9538):843–854. doi: 10.1016/S0140-6736(06)69121-6
  33. Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221–1237. doi: 10.1016/S1470-2045(17)30458-8
  34. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16. doi: 10.1016/s0360-3016(00)00663-5
  35. Hliniak A, Gwiazdowska B, Szutkowski Z, et al. A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time. Radiother Oncol. 2002;62(1):1-10. doi: 10.1016/s0167-8140(01)00494-7
  36. Ghosh–Laskar S, Kalyani N, Gupta T, et al. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial. Head Neck. 2016;38(2):202–207. doi: 10.1002/hed.23865
  37. Dische S, Saunders M, Barrett A, et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44(2):123–136. doi: 10.1016/S0167-8140(97)00094-7
  38. Bogaert Van den W, Schueren van der E, Horiot JС, et al. Early results of the EORTC randomized clinical trial on multiple fractions per day and misonidazole in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1986;12(4):587–591. doi: 10.1016/0360-3016(86)90067-2
  39. Marcial VA, Pajak TF, Chang С, et al. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int J Radial Oncol Biol Phys. 1987;13(1):41–47. doi: 10.1016/0360-3016(87)90258-6
  40. Jackson SM, Weir LM, Hay JH, et al. A randomized trial of accelerited versus conventional radiotherapy in head and neck cancers. Raidiother Oncol. 1997;43(1):39–46. doi: 10.1016/s0167-8140(97)01944-0
  41. Kanaev SV. Radiation therapy of malignant tumors of the head and neck. Practical Oncology. 2003;4(1):15–24. (In Russ). EDN: QIKTAB
  42. Zhang S, Zeng N, Yang J, He J, Zhu F, Liao W, Xiong M, Li Y. Advancements of radiotherapy for recurrent head and neck cancer in modern era. Radiat Oncol. 2023;18(1):166. doi: 10.1186/s13014-023-02342-0
  43. Solodkiy VA, Panshin GA, Titova VA, et al. Relapse-free survival in patients with malignant tumors of the oral mucosa after multicomponent treatment. P.A. Herzen Journal of Oncology. 2022;11(4):5–11. doi: 10.17116/onkolog2022110415
  44. Nevens D, Duprez F, Daisne JF, et al. Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control. Radiother Oncol. 2017;122(2):171–177. doi: 10.1016/j.radonc.2016.08.009
  45. Gladilina IA, Shabanov MA. Radiation and chemoradiotherapy treatment of advanced oropharyngeal cancer. Moscow; 2001. 164 p. (In Russ).
  46. Sokurenko VP. Rationale for the choice of radiation and chemoradiotherapy for patients with locally advanced cancer of the oropharynx and oral cavity stage III–IV [dissertation]. St. Petersburg; 2010. 45 p. (In Russ). EDN: QGVHDV
  47. Stukan AI, Murashko RA, Bodnya VN, et al. Topical issues of chemoradiotherapy for oropharyngeal squamous cell carcinoma: the efficiency and toxicity of chemotherapy regimens with the goal of radiomodification. P.A. Herzen Journal of Oncology. 2018;7(3):61–67. doi: 10.17116/onkolog20187361
  48. Schüttrumpf L, Marschner S, Scheu K, et al. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck — results from an unselected cohort of the clinical cooperation group “Personalized Radiotherapy in Head and Neck Cancer”. Radiat Oncol. 2020;15(1):7. doi: 10.1186/s13014-019-1452-4
  49. Müller von der Grün J, Martin D, Stöver T, et al. Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer. Biomed Res Int. 2018;2018:3508795. doi: 10.1155/2018/3508795
  50. Chitapanarux I, Tharavichitkul E, Kamnerdsupaphon P, et al. Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer. J Radiat Res. 2013;54:1110–1117. doi: 10.1093/jrr/rrt054
  51. Semin DYu, Mardynsky YuS, Medvedev VS, et al. Immediate and long-term results of simultaneous chemoradiotherapy in non-traditional modes of fractionation in the treatment of patients with oropharyngeal squamous cell carcinoma. Problems in Oncology. 2013;59(6):725–730. EDN: RTUROH
  52. Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006;6:28. doi: 10.1186/1471-2407-6-28
  53. Budach V, Stromberger C, Poettgen C, et al. Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6 Gy With Concurrent 5-FU/Mitomycin C is Superior to HART of 77.6 Gy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the ARO 95–06 Randomized Phase III Trial. Int J Radiat Oncol. 2015;91(5):916–924. doi: 10.1016/j.ijrobp.2014.12.034
  54. Petit C, Lacas B, Pignon JP, et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 2021;22(5):727–736. doi: 10.1016/S1470-2045(21)00076-0
  55. Morris ZS, Mohindra P, Kruser TJ. Combined Chemoradiation Therapy in the Treatment of Squamous Cell. Carcinoma of the Head and Neck—An Evolving Paradigm. Oncology & Hematology Review (US). 2013;9(2):115–121. doi: 10.17925/OHR.2013.09.2.115
  56. Porceddu SV, Scotté F, Aapro M, et al. Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy. Front. Oncol. 2020;9:1522. doi: 10.3389/fonc.2019.01522
  57. Iyer NG, Tan DSW, Tan VKM, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer 2015;121(10):1599–1607. doi: 10.1002/cncr.29251 Erratum in: Cancer. 2015;121(19):3560. doi: 10.1002/cncr.29500
  58. Bessell A, Glenny AM, Furness S, et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database Syst Rev. 2011;(9):CD006205. doi: 10.1002/14651858.CD006205.pub3. Update in: Cochrane Database Syst Rev. 2018;(12):CD006205. doi: 10.1002/14651858.CD006205.pub4
  59. Chauhan A, Sehgal SA, Khurana A, et al. Is Accelerated Radiation Therapy an Answer where Concurrent Chemoradiation is not Feasible for the Management of Locally Advanced Head and Neck Cancers? A Contribution to the Controvert. Clinics in Oncology. 2019;4:1664.
  60. LiuY, Kou C, Bai W, et al. Altered fractionation radiotherapy with or without chemotherapy in the treatment of head and neck cancer: a network meta-analysis. Onco Targets Ther. 2018;11:5465–5483. doi: 10.2147/OTT.S172018
  61. Budach V, Cho CH, Sedlmaier B, et al. Five years’ results of the German ARO 04-01 trial of concurrent 72Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer. J Clin Oncol. 2012;30(Suppl 15):5512. doi: 10.1200/jco.2012.30.15_suppl.5512
  62. Rades D, Zwaan I, Soror T, et al. Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cancers. 2023;15(13):3278. doi: 10.3390/cancers15133278
  63. Iocca O, Farcomeni A, Di Rocco A, et al. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and bayesian network meta-analysis of the currently available treatment options. Oral Oncol. 2018;80:40–51. doi: 10.1016/j.oraloncology.2018.03.001
  64. Sanderson RJ, Ironside JA. Squamous cell carcinomas of the head and neck BMJ. 2002;325(7368):822–827. doi: 10.1136/bmj.325.7368.822
  65. Denittis AS, Machtay M, Rosenthal DI, et al. Advanced oropharyngeal carcinoma treated with surgery and radiotherapy: oncologic outcome and functional assessment. Am J Otolaryngol. 2001;22(5):329–335. doi: 10.1053/ajot.2001.26492
  66. Podvyaznikov SO, Byakhov MJ. Experience of taxol application in chemotherapy of head and neck squamous cell carcinoma. Modern Oncology. 2002;4(3):126–130. EDN: XIQBNN
  67. Gladilina IA. Radiosensitization in radiation therapy of malignant tumors. Effective pharmacotherapy. Oncology, Hematology and Radiology. N.N. Blokhin Russian Oncology Research Center RAMS. 2011;(22):46–53. (In Russ). EDN: SGIALB
  68. Artamonova EV, Maznyuk LV. Skin toxicity of EGFR blockers (according to clinical studies of cetuximab). Effective pharmacotherapy. Oncology, Hematology and Radiology. NN. Blokhin Russian Oncology Research Center RAMS. 2012;(34):30–35. (In Russ). EDN: SJWIVL
  69. Lee B. Head and neck cancer: treatment & management. head and neck cancers [Updated 24 July 2024]. Available from: https://www.cancertherapyadvisor.com/ddi/head-and-neck-cancer-treatment/
  70. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2006;354:567–578. doi: 10.1056/NEJMoa053422
  71. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–28. doi: 10.1016/S1470-2045(09)70311-0 Erratum in: Lancet Oncol. 2010;11(1):14.
  72. Bonner JA, Giralt J, Harari P, et al. Cetuximab prolongs survival in patients with locally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol. 2004;22(14S):5507.
  73. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–11127. doi: 10.1056/NEJMoa0802656
  74. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–2177. doi: 10.1200/JCO.2006.06.7447
  75. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5578–5587. doi: 10.1200/JCO.2005.07.120
  76. Hitt R, Mesía R, Lozano A, et al. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer. Oral Oncol. 2022;134:106087. doi: 10.1016/j.oraloncology.2022
  77. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck. carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–2950. doi: 10.1200/JCO.2013.53.5633
  78. Garden AS, Morrison WH, Rosenthal DI, et al. Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol 2004;14(2):103–9. doi: 10.1053/j.semradonc.2003.12.004
  79. Chubenko VA. Complications of targeted therapy. Prakticheskaia onkologia. 2010;11(3):192–202. (In Russ).
  80. Healthyni CS, Subroto T, Megantara S, et al. Potential use of lapatinib in the treatment of head and neck squamous cell carcinoma (Review). World Academy of Sciences Journal. 2022;4(5):35. doi: 10.3892/wasj.2022.170
  81. Benasso M, Corvò R, Ponzanelli A, et al. Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck. Annals of Oncology. 2004;15:646–652. doi: 10.1093/annonc/mdh138
  82. Kurpeshev OK, Tsyb AF, Mardynskiy YuS, Berdov BA. The mechanism of development and ways of overcoming the chemoresistance of tumors. Part 1. Multidrug resistance of tumor cells. Russian Journal of Oncology. 2002;4:48–51. (In Russ). EDN: TLEYDD
  83. Kurpeshev OK, Tsyb AF, Mardinsky YuS, Berdov BA. Mechanisms of development and ways to overcome chemoresistance of tumors. Part 2. The role of the relationship between the stroma and tumor parenchyma in the effectiveness of chemotherapy. Russian Journal of Oncology. 2003;1:50–54. (In Russ). EDN: OKJFQP
  84. Kurpeshev OK, Tsyb AF, Mardynskiy YuS, Berdov BA. The mechanism of development and ways of overcoming the chemoresistance of tumors. Part 3. Possible ways to overcome tumor chemoresistance. Russian Journal of Oncology. 2003;2:50–53. (In Russ). EDN: OKJFWJ
  85. Stavrovskaya AA, Gens GP. Some new aspects of studies of multidrug resistance of tumor cells. Advances in molecular oncology. 2014;1(1):5–11. doi: 10.17650/2313-805X.2014.1.1.5-11
  86. Emran TB, Shahriar A, Mahmud AR, et al. Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Front Oncol. 2022; 12:891652. doi: 10.3389/fonc.2022.891652
  87. Zhou LY, Zhou LY. Research Advance of BCR-ABL Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia–Review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31(2):585–588. doi: 10.19746/j.cnki.issn.1009-2137.2023.02.040

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».